Status:
COMPLETED
A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Chemotherapy-Induced Nausea and Vomiting
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailab...
Eligibility Criteria
Inclusion
- Subject is in good health
- Subject is a nonsmoker
- Subject is willing to comply with the study restrictions
Exclusion
- Subject has a history of any illness that might confound the results of the study or might make participation in the study unsafe
- Subject has a history of stroke, seizures, or major neurological disorder
- Subject has a history of cancer
- Subject consumes more than two alcoholic drinks per day
- Subject consumes more than three caffeinated beverages daily
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00945321
Start Date
February 1 2009
End Date
March 1 2009
Last Update
January 28 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.